The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 869-874

  Mercer, Louise K ^a   Green, Adele C ^a,b   Galloway, James B ^a   Davies, Rebecca ^a   Lunt, Mark ^a   Dixon, William G ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a   Maiden, Nicola ^c   Price, Tom ^d   Hopkinson, Neil ^e   O'Reilly, Sheila ^f   Hordon, Lesley ^g   Griffiths, Ian ^h   Porter, Duncan ⁱ   Capell, Hilary ^j   Hassell, Andy ^k   Benitha, Romela ^l   Choy, Ernest ^m   Walsh, David ⁿ   Emery, Paul ^o   Knight, Susan ^p   Bruce, Ian ^q   Taggart, Allister ^r   Scott, David ^s   Thompson, Paul ^t   McCrae, Fiona ^u   Goodfellow, Rhian ^v   Kitas, George ^w   Jubb, Ronald ^x   Abernethy, Rikki ^y   Clarke, Shane ^z   Green, Sandra ^z   Sanders, Paul ^aa   Coulson, Amanda ^ab   Harrison, Bev ^ac   Bukhari, Marwan ^ad   Klimiuk, Peter ^ae   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ANTRIM AREA HOSPITAL   (United Kingdom)

^d ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^e Christchurch Hospital Dorset   (United Kingdom)

^f ROYAL DERBY HOSPITAL   (United Kingdom)

^g Dewsbury and District Hospital   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^j GLASGOW ROYAL INFIRMARY   (United Kingdom)

^k HAYWOOD HOSPITAL   (United Kingdom)

^l HOPE HOSPITAL   (United Kingdom)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ Kings Mill Centre ^*  (United Kingdom)

^o LEEDS GENERAL INFIRMARY   (United Kingdom)

^p MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^q MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^r MUSGRAVE PARK HOSPITAL   (United Kingdom)

^s NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^t POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^u QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^v ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^w RUSSELLS HALL HOSPITAL   (United Kingdom)

^x SELLY OAK HOSPITAL   (United Kingdom)

^y St Helens Hospital   (United Kingdom)

^z WESTON GENERAL HOSPITAL   (United Kingdom)

^aa WITHINGTON HOSPITAL   (United Kingdom)

^ab Withybush General Hospital   (United Kingdom)

^ac NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^ad ROYAL LANCASTER INFIRMARY   (United Kingdom)

^ae ROYAL OLDHAM HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KERATINOCYTE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PATIENT MONITORING; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; RHEUMATOID ARTHRITIS; SKIN CANCER; SKIN CARCINOMA; SKIN PROTECTION; STANDARDIZED INCIDENCE RATIO;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KERATINOCYTES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860915531     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200622     Document Type: Article

References (30)

1. McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol 2009;30:121-33.
2. Cancerstats. Skin cancer. Cancer Research, UK. http://info. cancerresearchuk.org/cancerstats/types/skin/ (accessed 29 June 2009).
3. Centers for Disease Control and Prevention. Skin cancer. http://www.cdc.gov/cancer/skin/ (accessed 4 Oct 2011).
4. Karagas MR, Greenberg ER, Spencer SK, et al. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999;81:555-9. (Pubitemid 29203052)
5. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001;45:528-36. (Pubitemid 32917246)
6. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11. (Pubitemid 23068804)
7. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7. (Pubitemid 26306889)
8. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
9. Esser AC, Abril A, Fayne S, et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004;50(5 Suppl):S75-7. (Pubitemid 38580526)
10. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6. (Pubitemid 41623851)
11. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Health and Clinical Excellence. http://guidance.nice.org.uk/TA36 (accessed 15 Oct 2008).
12. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumour necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of asalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiology & Drug Safety 2010;19:1-11.
13. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95. (Pubitemid 47502734)
14. Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1431-9.
15. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63. (Pubitemid 40277395)
16. Watson K, Symmons D, Griffiths I, et al. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64 Suppl 4:iv42-3. (Pubitemid 41532016)
17. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9. (Pubitemid 16033804)
18. Dickinson HO, Salotti JA, Birch PJ, et al. How complete and accurate are cancer registrations notified by the National Health Service Central Register for England and Wales? J Epidemiol Community Health 2001;55:414-22. (Pubitemid 32472880)
19. Goodwin RG, Holme SA, Roberts DL. Variations in registration of skin cancer in the United Kingdom. Clin Exp Dermatol 2004;29:328-30. (Pubitemid 38658491)
20. Clouser MC, Roe DJ, Foote JA, et al. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf 2009;18:276-83.
21. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000;143:1224-9. (Pubitemid 32052759)
22. 5-Year summary of incidence of non-melanoma skin cancer, basal cell carcinoma and squamous cell carcinoma in Scotland 2003-2007. http://www.isdscotland.org/isd/1048.html. ISD Scotland, (accessed 07 Sept 2010).
23. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
24. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6. (Pubitemid 27426150)
25. Hemminki K, Li X, Sundquist K, et al. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford) 2008;47:698-701. (Pubitemid 351619215)
26. Office for National Statistics. Cancer Statistics: Registrations Series MB1 - No. 39, 2008. Type: Internet Communication. http://ons.gov.uk/ons/ (accessed 11 July 2011).
27. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
28. Mercer, Galloway, Lunt et al. The Influence of anti-TNF therapy upon incidence of non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR) (abstract). ACR/ARPH Scientific Meeting 2009. 2009;2062 17-21 October 2009, Philadelphia, Pensylvania, USA.
29. Office for National Statistics. Summary quality report for cancer registration statistics. http://www.ons.gov.uk/about-statistics/methodology-and- quality/quality/qualinfo-economic-social-and-bus-stats/quality-reports-for- social-statistics/index.html (accessed 30 March 2011).
30. Marghoob A, Kopf AW, Bart RS, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol 1993;28:22-8. (Pubitemid 23019559)